Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.
scoring algorithm for C grade 2 diarrhea and skin rash in patients
Trastuzumab or lapatinib with standard chemotherapy for HER2
Update on systemic treatment for newly diagnosed inflammatory
Trastuzumab Offers Long-Term Survival Benefits in HER2+ Early
Efficacy and Tolerability of Lapatinib in the Management of Breast
HER-2 directed therapy in advanced breast cancer
Epidermal Growth Factor Receptor Inhibitors and Skin Rash
Anticancer pan-ErbB inhibitors reduce inflammation and tissue
Current Oncology, Free Full-Text
Dermatologic conditions in women receiving systemic cancer therapy
Adverse effects of tyrosine kinase inhibitors in cancer therapy
Multicenter Phase II Study of Neoadjuvant Lapatinib and
Management algorithm for lapatinib- associated rash for nurses
